Regular ArticleIdiopathic inflammatory myopathies – myositis
References (61)
- et al.
The epidemiology of polymyositis
American Journal of Medicine
(1970) - et al.
Juvenile dermatomyositis: a retrospective review of a 30-year experience
Journal of the American Academy of Dermatology
(2001) - et al.
Analysis of HLA-DM polymorphism in juvenile dermatomyositis (JDM) patients
Human Immunology
(1999) - et al.
Postpartum idiopathic polymyositis
Lancet
(1992) - et al.
Fetal microchimerism and inflammatory myopathies
Lancet
(2001) - et al.
Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies
Lancet
(2000) - et al.
Chimerism in children with juvenile dermatomyositis
Lancet
(2000) - et al.
Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study
Lancet
(2001) - et al.
NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy
Annals of Internal Medicine
(1995) Polymyositis, dermatomyositis and inclusion-body myositis
New England Journal of Medicine
(1991)
A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups
Medicine (Baltimore)
Myositis-specific autoantibodies. Touchstones for understanding the inflammatory myopathies
Journal of the American Medical Association
Polymyositis and dermatomyositis (first of two parts)
New England Journal of Medicine
Polymyositis and dermatomyositis (second of two parts)
New England Journal of Medicine
Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis
Medicine (Baltimore)
Classification and diagnostic criteria for polymyositis and dermatomyositis
Journal of Rheumatology
Classification criteria for the idiopathic inflammatory myopathies
Current Opinion in Rheumatology
Classification criteria for polymyositis and dermatomyositis
Journal of Rheumatology
Guidelines of care for dermatomyositis
Journal of the American Academy of Dermatology
Inclusion body myositis and myopathies
Annals of Neurology
Myositis-specific autoantibodies: overview and recent developments
Current Opinion in Rheumatology
New perspectives on the idiopathic inflammatory myopathies of childhood
Current Opinion in Rheumatology
Incidence of polymyositis–dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963–1982
Journal of Rheumatology
Epidemiologic features of diffuse connective tissue disorders in Rochester, Minn., 1951 through 1967, with special reference to systemic lupus erythematosus
Mayo Clinic Proceedings
Occurrence of polymyositis in the county of Gavleborg, Sweden
Scandinavian Journal of Rheumatology
Incidence of inflammatory myopathies in Victoria, Australia, and evidence of spatial clustering
Journal of Rheumatology
Epidemiology of polymyositis–dermatomyositis in Israel, 1960–76
Israel Journal of Medical Sciences
Epidemiology of neuromuscular diseases, including the postpolio sequelae, in a Swedish county
Neuroepidemiology
The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient
Annals of the Rheumatic Diseases
Inclusion body myositis. Observations in 40 patients
Brain
Cited by (24)
Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock?
2017, Autoimmunity ReviewsCitation Excerpt :Idiopathic inflammatory myopathies (IIMs) comprise a group of relatively rare muscle diseases (IIMs include dermatomyositis (DM), polymyositis (PM), sporadic inclusion body myositis (sIBM) and necrotizing myositis (NM)) that display heterogeneous clinical phenotypes and occur secondary to systemic disorders such as vasculitides or connective tissue disease [1–5]. The clinical characteristics of IIMs include progressive muscle weakness that is accompanied by intact sensitivity and tendon reflexes, muscle pain and elevated serum creatine kinase (CK) levels [1–3,6]. IIMs can be further distinguished by observing the pattern of affected muscles, patient's age at disease onset, additional involvement of organs, detected autoantibodies and response to treatment [1,3,4].
Idiopathic inflammatory myopathies
2012, Best Practice and Research: Clinical RheumatologyCitation Excerpt :Furthermore, the group of clinical disease IIMs can be divided into subgroups (Table 2). This clinical classification still creates very heterogeneous groups, although it has some predictive value of prognostic and therapeutic points of view [1–5]. We consider ‘definite DM’ the presence of three of diagnostic criteria (DC) 1, 2, 3 and 4 + skin rashes; ‘probable DM’ when the patient has two of DCs 1, 2, 3, 4 + skin rashes; and ‘possible DM’ one of DCs + skin rashes.
Targeted Treatment of the Idiopathic Inflammatory Myopathies
2010, Targeted Treatment of the Rheumatic DiseasesTargeted treatment of the idiopathic inflammatory myopathies
2009, Targeted Treatment of the Rheumatic Diseases: Expert ConsultPseudoxanthoma elasticum and polymyositis in a child [12]
2006, Journal of the American Academy of Dermatology
- f1
All correspondence to: Ingrid E. Lundberg. Tel: +46-8-5177 6087; Fax: +46-8-5177 3080; E-mail: [email protected]